Office of the Director, National Institutes of Health; Notice of Meeting, 25248 [E9-12208]
Download as PDF
erowe on PROD1PC63 with NOTICES
25248
Federal Register / Vol. 74, No. 100 / Wednesday, May 27, 2009 / Notices
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel, 8120 Wisconsin
Ave., Bethesda, MD 20814.
Contact Person: Joyce C. Pegues, BS, BA,
PhD, Scientific Review Officer, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 7149, Bethesda, MD 20892–8329, 301–
594–1286, peguesj@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Physical
Sciences—Oncology Center.
Date: June 29–30, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott North Conference
Center, 5701 Marinelli Road, Rockville, MD
20852.
Contact Person: Kenneth L. Bielat, BS,
PhD, Scientific Review Officer, Special
Review Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 7147, Bethesda, MD 20892–8329,
301496–7576, bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Comprehensive Minority Institution/Cancer
Center Partnership.
Date: July 16–17, 2009.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Legacy Hotel, 1775 Rockville
Pike, Rockville, MD 20852.
Contact Person: Joyce C. Pegues, BS, BA,
PhD, Scientific Review Officer, Special
Review and Logistics Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 6116 Executive Boulevard,
Room 7149, Bethesda, MD 20892–8329, 301–
594–1286, peguesj@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Biospecimen Prep.
Date: July 21, 2009.
Time: 8 a.m. to 11a.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Alexandria at Old Town,
1767 King Street, Alexandria, VA 22314.
Contact Person: Marvin L. Salin, PhD,
Scientific Review Officer, Special Review
and Logistics Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 7073,
Bethesda, MD 20892–8329, 301–496–0694,
msalin@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
VerDate Nov<24>2008
15:23 May 26, 2009
Jkt 217001
Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–12206 Filed 5–26–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Recombinant DNA
Advisory Committee.
Date: June 16–17, 2009.
Time: June 16, 2009, 2 p.m. to 5:30 p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as a
discussion of Biosafety Considerations for the
Cloning of the Risk Group 4
Mononegavirales: Marburg, Nipah and
Hendra viruses—in Non-Pathogenic E. coli.
Please check the meeting agenda at https://
oba.od.nih.gov/rdna.html for more
information.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Floor 6C, Room
6, Bethesda, MD 20892.
Time: June 17, 2009, 8:15 a.m. to 3 p.m.
Agenda: The Recombinant DNA Advisory
Committee will review and discuss selected
human gene transfer protocols as well as
related data management activities. Please
check the meeting agenda at https://
oba.od.nih.gov/rdna.html for more
information.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Floor 6C, Room
6, Bethesda, MD 20892.
Contact Person: Laurie Lewallen, Advisory
Committee Coordinator, Office of
Biotechnology Activities, National Institutes
of Health, 6705 Rockledge Drive, Room 750,
Bethesda, MD 20892–7985. 301–496–9838.
lewallla@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www4.od.nih.gov/oba/, where an agenda and
any additional information for the meeting
will be posted when available.
OMB’s ‘‘Mandatory Information
Requirements for Federal Assistance Program
Announcements’’ (45 FR 39592, June 11,
1980) requires a statement concerning the
official government programs contained in
the Catalog of Federal Domestic Assistance.
Normally NIH lists in its announcements the
number and title of affected individual
programs for the guidance of the public.
Because the guidance in this notice covers
virtually every NIH and Federal research
program in which DNA recombinant
molecule techniques could be used, it has
been determined not to be cost effective or
in the public interest to attempt to list these
programs. Such a list would likely require
several additional pages. In addition, NIH
could not be certain that every Federal
program would be included as many Federal
agencies, as well as private organizations,
both national and international, have elected
to follow the NIH Guidelines. In lieu of the
individual program listing, NIH invites
readers to direct questions to the information
address above about whether individual
programs listed in the Catalog of Federal
Domestic Assistance are affected.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–12208 Filed 5–26–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
E:\FR\FM\27MYN1.SGM
27MYN1
Agencies
[Federal Register Volume 74, Number 100 (Wednesday, May 27, 2009)]
[Notices]
[Page 25248]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-12208]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director, National Institutes of Health; Notice of
Meeting
Pursuant to section 10(a) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Recombinant DNA Advisory Committee.
The meeting will be open to the public, with attendance limited to
space available. Individuals who plan to attend and need special
assistance, such as sign language interpretation or other reasonable
accommodations, should notify the Contact Person listed below in
advance of the meeting.
Name of Committee: Recombinant DNA Advisory Committee.
Date: June 16-17, 2009.
Time: June 16, 2009, 2 p.m. to 5:30 p.m.
Agenda: The Recombinant DNA Advisory Committee will review and
discuss selected human gene transfer protocols as well as a
discussion of Biosafety Considerations for the Cloning of the Risk
Group 4 Mononegavirales: Marburg, Nipah and Hendra viruses--in Non-
Pathogenic E. coli. Please check the meeting agenda at https://oba.od.nih.gov/rdna.html for more information.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Floor 6C, Room 6, Bethesda, MD 20892.
Time: June 17, 2009, 8:15 a.m. to 3 p.m.
Agenda: The Recombinant DNA Advisory Committee will review and
discuss selected human gene transfer protocols as well as related
data management activities. Please check the meeting agenda at
https://oba.od.nih.gov/rdna.html for more information.
Place: National Institutes of Health, Building 31, 31 Center
Drive, Floor 6C, Room 6, Bethesda, MD 20892.
Contact Person: Laurie Lewallen, Advisory Committee Coordinator,
Office of Biotechnology Activities, National Institutes of Health,
6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985. 301-496-
9838. lewallla@od.nih.gov.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has instituted stringent
procedures for entrance onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles will be inspected
before being allowed on campus. Visitors will be asked to show one
form of identification (for example, a government-issued photo ID,
driver's license, or passport) and to state the purpose of their
visit.
Information is also available on the Institute's/Center's home
page: https://www4.od.nih.gov/oba/, where an agenda and any
additional information for the meeting will be posted when
available.
OMB's ``Mandatory Information Requirements for Federal
Assistance Program Announcements'' (45 FR 39592, June 11, 1980)
requires a statement concerning the official government programs
contained in the Catalog of Federal Domestic Assistance. Normally
NIH lists in its announcements the number and title of affected
individual programs for the guidance of the public. Because the
guidance in this notice covers virtually every NIH and Federal
research program in which DNA recombinant molecule techniques could
be used, it has been determined not to be cost effective or in the
public interest to attempt to list these programs. Such a list would
likely require several additional pages. In addition, NIH could not
be certain that every Federal program would be included as many
Federal agencies, as well as private organizations, both national
and international, have elected to follow the NIH Guidelines. In
lieu of the individual program listing, NIH invites readers to
direct questions to the information address above about whether
individual programs listed in the Catalog of Federal Domestic
Assistance are affected.
(Catalogue of Federal Domestic Assistance Program Nos. 93.14,
Intramural Research Training Award; 93.22, Clinical Research Loan
Repayment Program for Individuals from Disadvantaged Backgrounds;
93.232, Loan Repayment Program for Research Generally; 93.39,
Academic Research Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187,
Undergraduate Scholarship Program for Individuals from Disadvantaged
Backgrounds, National Institutes of Health, HHS)
Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-12208 Filed 5-26-09; 8:45 am]
BILLING CODE 4140-01-P